San Diego-dependent Viking Therapeutics marked itself as a serious competitor in the weight loss drug current market in February right after revealing promising facts from the mid-stage trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when presented for a weekly injection As well as in March